

# Vimentin Ab-2 (Clone V9)

Mouse Monoclonal Antibody

Cat. # DLN-07298, DLN-07299, or DLN-07297 (0.1ml, 0.5ml, or 1.0ml at 200µg/ml) Cat. #DLN-07300 or DLN-07301 (0.1ml or 0.2ml at 1.0mg/ml) (Purified Ab without BSA and Azide) Cat. #DLN-07295, DLN-07296, or DLN-07294 (0.1ml, 0.5ml, or 1.0ml at 200µg/ml) (Biotin-labeled Ab with BSA and Azide) Cat. # DLN-07302 (7.0ml)

**Description:** Vimentin is the main intermediate filament protein in mesenchymal cells and is therefore of value in the differential diagnosis of undifferentiated neoplasms.

Mol. Wt. of Antigen: 57-60kDa

*Epitope:* Not determined

*Species Reactivity:* Human, Monkey, Cow, Horse, Pig, Rabbit, Dog, Cat, Rat, Mouse, Hamster, Gerbil, and Chicken. Others-not known.

Clone Designation: V9

Ig Isotype / Light Chain:  $IgG_1/\kappa$ 

Immunogen: Purified vimentin from pig eye lens

#### **Applications and Suggested Dilutions:**

- Immunoprecipitation (Native and denatured) (Use Protein G) (Ab 2µg/mg protein lysate)
- Western Blotting (Ab 1-2µg/ml for 2hrs at RT)
- Immunohistology (Formalin/paraffin) (Ab 0.25-0.5µg/ml for 30 min at RT)
- \* [Staining of formalin-fixed tissues REQUIRES boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min.]

The optimal dilution for a specific application should be determined by the investigator.

Positive Control: HUVEC, HeLa cells. Sarcomas.

Cellular Localization: Cytoplasmic

#### Supplied As:

200µg/ml antibody purified from the ascites fluid by Protein G chromatography. Prepared in 10 mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide. Also available without BSA and azide at 1mg/ml.

or

Prediluted antibody which is ready-to-use for staining of formalin-fixed, paraffin-embedded tissues.

dianova GmbH Warburgstr. 45 ● 20354 Hamburg Telefon (040)45067-0 ● Telefax (040) 45067-490 ● www.dianova.de



# Vimentin Ab-2 (Clone V9)

Mouse Monoclonal Antibody

Cat. # DLN-07298, DLN-07299, or DLN-07297 (0.1ml, 0.5ml, or 1.0ml at 200µg/ml)

Cat. #DLN-07300 or DLN-07301 (0.1ml or 0.2ml at 1.0mg/ml) (Purified Ab without BSA and Azide) Cat. #DLN-07295, DLN-07296, or DLN-07294 (0.1ml, 0.5ml, or 1.0ml at 200µg/ml) (Biotin-labeled Ab with BSA and Azide) Cat. # DLN-07302 (7.0ml)

Storage and Stability:

Ab with sodium azide is stable for 24 months when stored at 2-8°C. Antibody WITHOUT sodium azide is stable for 36 months when stored at below 0°C.

#### Key References:

- 1. Uusitalo M; et al. Investigative Ophthalmology and Visual Science, 1995 Dec, 36(13):2584-91.
- 2. Abeln EC; et al. British Journal of Cancer, 1994 Aug, 70(2):255-62.

#### Limitations and Warranty:

Our products are intended FOR RESEARCH USE ONLY and are not approved for clinical diagnosis, drug use or therapeutic procedures. No products are to be construed as a recommendation for use in violation of any patents. We make no representations, warranties or assurances as to the accuracy or completeness of information provided on our data sheets and website. Our warranty is limited to the actual price paid for the product. Dianova is not liable for any property damage, personal injury, time or effort or economic loss caused by our products.

#### Material Safety Data:

This product is not licensed or approved for administration to humans or to animals other than the experimental animals. Standard Laboratory Practices should be followed when handling this material. The chemical, physical, and toxicological properties of this material have not been thoroughly investigated. Appropriate measures should be taken to avoid skin and eye contact, inhalation, and ingestion. The material contains 0.09% sodium azide as a preservative. Although the quantity of azide is very small, appropriate care should be taken when handling this material as indicated above. The National Institute of Occupational Safety and Health has issued a bulletin citing the potential explosion hazard due to the reaction of sodium azide with copper, lead, brass, or solder in the plumbing systems. Sodium azide forms hydrazoic acid in acidic conditions and should be discarded in a large volume of running water to avoid deposits forming in metal drainage pipes.

For Research Use Only



## Vimentin Ab-2 (Clone V9)

Mouse Monoclonal Antibody

Cat. # DLN-07298, DLN-07299, or DLN-07297 (0.1ml, 0.5ml, or 1.0ml at 200µg/ml)

Cat. #DLN-07300 or DLN-07301 (0.1ml or 0.2ml at 1.0mg/ml) (Purified Ab without BSA and Azide) Cat. #DLN-07295, DLN-07296, or DLN-07294 (0.1ml, 0.5ml, or 1.0ml at 200µg/ml) (Biotin-labeled Ab with BSA and Azide)

Cat. # DLN-07302 (7.0ml)

#### Additional Key References:

- 1. Uusitalo M; Kivela T. Development of cytoskeleton in neuroectodermally derived epithelial and muscle cells of the human eye. Investigative Ophthalmology and Visual Science, 1995 Dec, 36(13):2584-91.
- 2. Abeln EC; Corver WE; Kuipers-Dijkshoorn NJ; Fleuren GJ; Cornelisse CJ. Molecular genetic analysis of flow-sorted ovarian tumour cells: improved detection of loss of heterozygosity. British Journal of Cancer, 1994 Aug, 70(2):255-62.
- 3. Olah I; Glick B. Anti-vimentin monoclonal antibodies differentiate two resident cell populations in chicken spleen. Developmental and Comparative Immunology, 1994 Jan-Feb, 18(1):67-73.
- Evans DL; Harris DT; Leary JH 3d; St John AL; Jaso-Friedman L. Identification of a vimentin-like function associated molecule (FAM) on rat NK cells: evidence for receptor function. Scandinavian Journal of Immunology, 1993 Feb, 37(2):131-42.
- 5. Heatley M; Whiteside C; Maxwell P; Toner P. Vimentin expression in benign and malignant breast epithelium. Journal of Clinical Pathology, 1993 May, 46(5):441-5.
- 6. Jaso-Friedmann L; Leary JH 3d; Evans DL. Nonspecific cytotoxic cells in fish: antigenic cross-reactivity of a function associated molecule with the intermediate filament vimentin. Cellular Immunology, 1993 Apr 15, 148(1):208-17.
- Uusitalo M; Kivela T; Tarkkanen A. Identification of a novel element in the human eye: the inner connective tissue layer of the ciliary body characterized with antibodies to the HNK-1 epitope. Investigative Ophthalmology and Visual Science, 1993 Jun, 34(7):2372-81.
- 8. Bohn W; Wiegers W; Beuttenmuller M; Traub P. Species-specific recognition patterns of monoclonal antibodies directed against vimentin. Experimental Cell Research, 1992 Jul, 201(1):1-7.
- 9. Fuchs U; Kivela T; Summanen P; Immonen I; Tarkkanen A. An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma. American Journal of Pathology, 1992 Jul, 141(1):169-81.
- 10. Kim JM; Su WP; Kurtin PJ; Ziesmer S. Marjolin's ulcer: immunohistochemical study of 17 cases and comparison with common squamous cell carcinoma and basal cell carcinoma. Journal of Cutaneous Pathology, 1992 Aug, 19(4):278-85.
- 11. Kivela T; Fuchs U; Tarkkanen A. Cytoskeleton in neuroectodermally derived epithelial and muscle cells of the human iris and ciliary body. Journal of Histochemistry and Cytochemistry, 1992 Oct, 40(10):1517-26.
- 12. Tamimi HK; Gown AM; Kim-Deobald J; Figge DC; Greer BE; Cain JM. The utility of immunocytochemistry in invasive adenocarcinoma of the cervix. American Journal of Obstetrics and Gynecology, 1992, 166:1655-61; discussion 1661-2.
- 13. Ciesielski-Treska J; Ulrich G; Aunis D. Protein kinase C-induced redistribution of the cytoskeleton and phosphorylation of vimentin in cultured brain macrophages. Journal of Neuroscience Research, 1991 Jul, 29(3):362-78.
- 14. Daste G; Serre G; Mauduyt MA; Vincent C; Caveriviere P; Soleilhavoup JP. Immunophenotyping of mesothelial cells and carcinoma cells with monoclonal antibodies to cytokeratins, vimentin, CEA and EMA improves the cytodiagnosis of serous effusions. Cytopathology, 1991, 2(1):19-28.
- Gustmann C; Altmannsberger M; Osborn M; Griesser H; Feller AC. Cytokeratin expression and vimentin content in large cell anaplastic lymphomas and other non-Hodgkin's lymphomas. American Journal of Pathology, 1991 Jun, 138(6):1413-22.
- 16. Nagle RB; Brawer MK; Kittelson J; Clark V. Phenotypic relationships of prostatic intraepithelial neoplasia to invasive prostatic carcinoma. American Journal of Pathology, 1991 Jan, 138(1):119-28.
- 17. Olah I; Kendall C; Glick B. Endogenous peroxidase- and vimentin-positive cells accumulate at the corticomedullary border of the chicken thymus. Poultry Science, 1991 May, 70(5):1144-52.
- 18. Wollina U; Berger U; Mahrle G. Immunohistochemistry of porcine skin. Acta Histochemica, 1991, 90(1):87-91.
- 19. Brockmann M; Brockmann I; Fischer M; Muller KM. Reactive lesions of the pleura. Immunohistochemical characterization. Pathology, Research and Practice, 1990 Apr, 186(2):238-46.
- 20. Carbone A; Gloghini A; Volpe R; Boiocchi M. Anti-vimentin antibody reactivity with Reed-Sternberg cells of Hodgkin's disease. Virchows Archiv. a, Pathological Anatomy and Histopathology, 1990, 417(1):43-8.

### dianova GmbH Warburgstr. 45 ● 20354 Hamburg Telefon (040)45067-0 ● Telefax (040) 45067-490 ● www.dianova.de



### Vimentin Ab-2 (Clone V9)

Mouse Monoclonal Antibody

Cat. # DLN-07298, DLN-07299, or DLN-07297 (0.1ml, 0.5ml, or 1.0ml at 200µg/ml)

Cat. #DLN-07300 or DLN-07301 (0.1ml or 0.2ml at 1.0mg/ml) (Purified Ab without BSA and Azide) Cat. #DLN-07295, DLN-07296, or DLN-07294 (0.1ml, 0.5ml, or 1.0ml at 200µg/ml) (Biotin-labeled Ab with BSA and Azide)

Cat. # DLN-07302 (7.0ml)

- 21. Gloghini A; Volpe R; Carbone A. Ki-M6 immunostaining in routinely processed sections of reactive and neoplastic human lymphoid tissue. Am Journal of Clinical Pathology, 1990, 94(6):734-41.
- 22. Gloghini A; Volpe R; Carbone A. Vimentin immunostaining in fibroblastic reticulum cells within human reactive and neoplastic lymphoid follicles. Human Pathology, 1990 Aug, 21(8):792-8.
- 23. Hirano T; Gluckman JL; deVries EJ. The expression of alpha vascular smooth-muscle actin in salivary gland tumors. Archives of Otolaryngology -- Head and Neck Surgery, 1990 Jun, 116(6):692-6.
- 24. Meyer SA; Ingraham CA; McCarthy KD. Expression of vimentin by cultured astroglia and oligodendroglia. Journal of Neuroscience Research, 1989 Oct, 24(2):251-9.
- 25. Gustafsson H; Virtanen I; Thornell LE. Expression of cytokeratins and vimentin in salivary gland carcinomas as revealed with monoclonal antibodies. Virchows Archiv. a, Pathological Anatomy and Histopathology, 1988, 412(6):515-24.